China lung cancer kurapa mishonga

Kufamba China lung cancer kurapa mishonga inogona kuve yakaoma. Gwara iri rinopa mishonga yakajairwa, kusanganisira yakanangidzirwa kurapa uye immunotharodies, pamwe neruzivo rwemapapu emapapu mishau yekona yehutachiona Kunzwisisa mhando dzekenza yemapapu uye sarudzo dzekurapa dzakakosha kune varwere nemhuri yavo.Types of lung cancerthe maviri makuru emhando dzepamheni.Isiri-diki cell lung cancer (NSCLC): Iyi ndiyo mhando yakajairika, accounting kweanenge 80-85% yekona yemapapu. Subtypspesi inosanganisira adenocarcinma, squamous cell carcinoma, uye yakakura cell carcoma.Diki Cell Lung Cancer (SCLC): Iyi mhando ishoma uye inowanzo kukura uye nekuparadzira nekukurumidza kupfuura nscarrapyrapyrapyrapyrapyrapyrapyrapy marerapyrapycherapycherapycherapy Mishonga yeComotherapy Inoshandiswa kuChina yeCancer yePlung inosanganisira:Platinum-based mishonga: Cisplatin, carboplatinTaxani: Paclitaxel, docetaxelGemcitabineVinouredzeraPemetrexedIyi mishonga inowanzoshandiswa musanganiswa, uye iyo chaiyo regimen ichaenderana nemhando uye nhanho yegomarara remapapu, pamwe nehutano hwese hwemurwere. Target Iyi mishonga inowanzoshandiswa ye nsclc ine chaiyo genetic mutatic mutati (epidermal kukura kwechimiro chefoni Zvakajairika EGFR Inhibitors inowanikwa muChina inosanganisira:GishinibibErlotinibAfatinibOsimortinibALK Inhibitark (Anaplastic Lymphoma Kinase) Inhibitors anoshandiswa kune varwere ne NSCLC vane ALK GECARRANCE. Zvakajairika ALK Inhibitors inowanikwa muChina inosanganisira:CrizotinibCeritinibAlectinibVamwe vakanangwa varapi vakarongedzwa marapirwo ekurapa anogona kushandiswa zvichienderana neyakajairika genetic muzvikamu zvirimo mumasero cancer. Izvi zvinosanganisira:Ros1 Inhibitors: Kune varwere vane ros1 gene kumashure.Braf Inhibitors: Kune varwere vane braf shanduro.Kusangana inhibitors: Kune varwere vakasangana neExon 14 Skipping mishonga.immunotsurapy mishonga yegomarara muChinaMunotsurapy mishonga inobatsira immune system yemuviri anoziva uye kurwisa cccer cancer. Iyi mishonga inowanzoshandiswa kufambira mberi NSCLC-1 / PD-L1 Inhibitorspd-1 (yakarongedzwa SEFTERPD CLEW-LIGAND-Ligbits Zvakajairika PD-1 / PD-L1 Inhibitors inowanikwa muChina inosanganisira:PembrolizumabNivolumabAREZZOZUMABDurvalumabSintilimabTislelizumabIzvi zvinodhaka zvinogona kushandiswa wega kana musanganiswa ne chomotherapy.clinal miedzo yegomarara muChinakarinari Muedzo unopa varwere vatsva uye mitsva yekenza yemapapu. Zvipatara zvakawanda uye nzvimbo dzekutsvagisa muChina dzinopa maClinic miedzo yekenza yemapapu. Varwere vanogona kutsvaga miedzo yekiriniki kuburikidza nemawebhusaiti senge Vanikamicker.gov uye Chinese zvinodhaka (中国药物临床试验登记与信息公示平台) .access kumishonga yemapapu ye cancer muChiraaccess kusvika China lung cancer kurapa mishonga inogona kusiyanisa zvichienderana nezvinhu zvakadai seinishuwarenzi yekuvhara uye mafomu echipatara. Zvinodhaka zvakawanda zvinogadzirwa zvino zvakabatanidzwa muNational Kudzorera zvinodhaka zvinodhaka (NRDL), izvo zvinogona kuderedza zvakanyanya mutengo wevarwere. Iyo inokurudzirwa kubvunza nezvevaridzi vazhinji uye vagari vehutano kuti vanzwisise sarudzo dziripo uye kufambisa hurongwa hwehutano. Shandong baofa cancer research Institute (jasonanagement.com) dzakatsaurirwa kufambira mberi kurapwa kenza uye kutsvakwa, kuona kuti varwere vanokwanisa kuwana marapirwo anonyanya kuvimbisa kuwanikwa, kusanganisira mutsva China lung cancer kurapa mishonga.Nonavigating kurapwa mutengo mutengo mutengo wemapapu cancer cancer cancer inogona kuve yakakosha. Kunzwisisa kweinishuwarenzi kufukidzwa, zvirongwa zviripo zvemari zviripo, uye NRRL inogona kubatsira varwere mari yekurapa. Kuongorora sarudzo nevashandi vezvemagariro uye vanopa mazano ezvipatara zvinoenderana nemishonga yechinyakare yeChinese Vamwe varwere vanowana TCM kubatsira mukugadzirisa mhedzisiro uye kugadzirisa hupenyu hwehupenyu. Nekudaro, zvakakosha kukurukura nezvekushandiswa kweTCM neyekuona kwako kuti ive yakachengeteka uye isingakwanisi kurapa kwemanyokisheni ekurapa. Mamiriro ezvinhu akajairika anosanganisira kupera simba, kusvotwa, kurutsa, manyoka, uye ganda remaganda. Kugadzirisa mhedzisiro chikamu chakakosha chehurongwa hwekurapa. Chikwata chako chehutano chinogona kupa nhungamiro pamabatirwo ehupenyu uye nekuvandudza hupenyu hwako hwekurapa mumapapu emapapu muChinathe munda wegomarara kurapa kuri kukurumidza kubuda. Gara uchiziviswa nezvezvazvino kufambira mberi mukati China lung cancer kurapa mishonga uye inoswedera nekubvunza neako hutano muridzi wehutano uye kugara kumusoro-kune-kufambidzana nemabhuku ekurapa. Tsvagurudzo kubva kumisangano yakaita Sangano Rinobva kuSandong Baofa cancer Information Institute inogara ichiparira kusvika pakukura ruzivo rwechenjerera. Pfupiso yemari yakajairika yemapapu mishonga muChinathis tafura inopfupisa mishonga yakajairika inoshandiswa kurapwa kwemapapu muChina. Mishonga yemhando yemhando mienzaniso yakajairika kushandisa chokotherapy Cisplatin PD-1 / PD-L1 Inhibitors Pembrolizumab, NIVOLUBAR Kubatsira Immune System kurwa cancer Disiki: Ruzivo urwu nderwe zvinangwa zvezivo chete uye hazvifanirwe kufungwa nezano rokurapa. Gara uchibvunza neanokodzera hutano hwehutano hwekuongororwa uye kurapwa kwegomarara remapapu. Bvunza chiremba wako usati waita chero sarudzo zvine chekuita nekurapa kwako kana kurapwa. Gara uchitsvaga zano rehunyanzvi hwekurapa kune chero mibvunzo nezve yako chaiyo mamiriro.